Loading...
01/10 06:00
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary suggests mixed signals: positive revenue growth and ASP expansion are countered by challenges in achieving ASP targets and addressing payment denials. The Q&A section reveals management's unclear responses on key metrics, raising concerns. However, the strategic plan for 2025 shows optimism with new biomarker launches and potential pharma partnerships. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
Revenue Growth Year-to-date revenue grew by 19%, driven by 8% growth in testing volume and 9% growth in ASP. This growth is attributed to the synergistic impact of volume and reimbursement growth moving in the same direction.
Q3 Revenue Revenue for Q3 2025 was $17.2 million, the highest quarter in history, representing a nearly 40% increase over Q3 2024. Even after accounting for over $1 million in downside revenue adjustments in Q3 2024, the growth was over 25%. This growth was driven by a 15% increase in CTD test volume year-over-year and almost 2% sequentially.
Pharma Services Revenue Pharma Services generated $780,000 in revenue in Q3 2025, bringing the year-to-date total to $1.2 million, compared to $100,000 in 2024. The growth is attributed to a strong business development team and an expanding order backlog of $3.5 million.
Gross Margin Gross margin for Q3 2025 was just over 58%, up about 260 bps compared to Q3 2024. Year-to-date gross margin was just over 59%, up about 60 bps over the same period in 2024. The improvement is due to ASP improvements and favorable per-test costs offsetting ASP headwinds.
Operating Expenses Operating expenses for Q3 2025 were $13.2 million, up from $11.6 million in Q3 2024. The increase is due to higher R&D spending for PAD4 and other pipeline initiatives, as well as SG&A costs associated with sales territory expansion and commercial leadership additions.
Net Loss Net loss for Q3 2025 was $7 million, compared to $5 million in Q3 2024. The increase includes about $3 million in noncash expenses related to fair value adjustments from a new debt facility. Adjusted EBITDA loss improved to $1.9 million in Q3 2025 from $4 million in Q3 2024.
Cash Position The company ended Q3 2025 with $35.7 million in cash and cash equivalents, up from $30 million at the end of Q2 2025. This improvement was supported by $3.4 million raised through ATM sales and net cash generation of $2.3 million during the quarter.
Launch of anti-PAD4 antibodies assays: Successfully launched assays for the detection of anti-PAD4 antibodies, a novel rheumatoid arthritis biomarker. This is the second biomarker launched this year. The product differentiates the rheumatoid arthritis offering and enhances clinical utility by identifying serological abnormalities in ambiguous cases. The development cost was under $3 million, with expected revenue payback in less than 24 months.
Enhanced rheumatoid arthritis profiling: With the addition of RA33 and anti-PAD4 antibodies, the serologic profiling now captures approximately 85% of rheumatoid arthritis patients, improving diagnostic precision and treatment guidance.
Territorial expansion: Expanded to 45 sales territories, up from 42. Two new territories emerged as top-performing growth areas, with others showing similar trends. This expansion is contributing to increased physician engagement and order volumes.
Pharma and CRO business growth: Generated $800,000 in Q3 revenue, with a year-to-date total of $1.2 million. The order backlog stands at $3.5 million, indicating strong momentum in this segment.
Revenue growth: Achieved a 19% year-to-date revenue growth, driven by an 8% increase in testing volume and a 9% rise in ASP. Q3 revenue was $17.2 million, the highest in company history.
Gross margin improvement: Gross margin improved to 58% in Q3, up 260 bps compared to Q3 2024, driven by ASP improvements and cost management.
Focus on ASP growth: Trailing 12-month ASP for CTD tests increased by 9% year-over-year to $441. Efforts are ongoing to address reimbursement challenges and further improve ASP.
Cash flow and financial positioning: Ended Q3 with $35.7 million in cash and equivalents, up from $30 million in Q2. The company is on track to achieve positive free cash flow, though sustained cash flow positivity may be delayed to 2026.
ASP (Average Selling Price) Challenges: The company is facing slower-than-expected ASP growth due to delayed reimbursement ramp-up for new biomarkers and the loss of a high ASP direct bill account. This is impacting revenue and bottom-line performance.
Revenue Cycle and Payer Education: Efforts to improve reimbursement through appeals, revenue cycle operations, and payer education are progressing slower than anticipated, leading to muted ASP gains.
Cash Flow Positivity: The timeline for achieving sustained cash flow positivity may be delayed to 2026 due to ASP challenges and other financial pressures.
Pharma Services Revenue Volatility: The pharma services revenue stream is described as 'lumpy,' with unpredictable timing of deliverables and revenue recognition, which could impact financial stability.
Operating Expenses: Increased R&D and SG&A expenses, including costs for new sales territories and leadership additions, are contributing to higher operating expenses, which could strain profitability.
Debt and Non-Cash Expenses: The company reported $3 million in non-cash expenses related to fair value adjustments from a new debt facility, contributing to a net loss for the quarter.
Revenue Expectations: The company expects to deliver $65 million to $70 million in revenue for 2025, with the potential to be cash flow positive at the high end of this range. However, sustained cash flow positivity may be delayed until 2026 due to ASP challenges.
Market Trends and Business Segment Performance: The AVISE CTD testing volume trajectory remains strong, with Q3 volume being the highest recorded for a third quarter period. Volume remained strong into October, indicating positive trends for Q4. Expansion into new territories is contributing meaningfully, with two recent territories emerging as top-performing growth areas.
ASP (Average Selling Price) Projections: Trailing 12-month ASP for CTD is currently at $441, a 9% increase year-over-year. However, the company is not seeing the full second-half ASP expansion anticipated. Efforts around appeals, revenue cycle operations, and payer education are expected to drive incremental progress, but gains are coming more gradually than expected.
Pharma and CRO Business: The company has a growing order backlog of $3.5 million in the Pharma and CRO business, with year-to-date revenue of $1.2 million. This segment is expected to continue expanding, although revenue recognition may be lumpy.
Biomarker Innovation and Revenue Impact: The launch of anti-PAD4 antibodies and other biomarkers is expected to moderately expand ASP in Q4 as payment history is established. The company anticipates a revenue payback for these efforts in less than 24 months, with a relatively small investment of under $3 million.
Gross Margin Projections: Gross margin is currently near 60%, with a path to mid-60s over time through further ASP expansion and cost management.
The selected topic was not discussed during the call.
The earnings call summary suggests mixed signals: positive revenue growth and ASP expansion are countered by challenges in achieving ASP targets and addressing payment denials. The Q&A section reveals management's unclear responses on key metrics, raising concerns. However, the strategic plan for 2025 shows optimism with new biomarker launches and potential pharma partnerships. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
The earnings call reveals strong financial performance with improved gross margins and sustainable volume growth. Management is confident in achieving the ASP increase, and the strategic expansion of territories and pipeline developments are promising. Despite some increase in operating expenses and net loss, the company is on track for positive adjusted EBITDA and free cash flow. The Q&A section supports the positive outlook, highlighting market potential and strategic initiatives. While management avoided specific guidance on volume, the overall sentiment remains positive with expectations of continued growth.
The earnings call presents mixed signals. While revenue increased by 8% and there's a positive outlook for new biomarker launches, gross margin slightly declined and net loss widened. The new credit facility and debt refinancing are positive, enhancing financial flexibility. However, management's vague guidance, especially regarding volume and margins, introduces uncertainty. The Q&A reveals cautious optimism but lacks clarity on future growth. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
The earnings call presents a mixed picture: revenue increased by 8%, but gross margin slightly decreased, and net loss widened. The company's strategic initiatives, such as new biomarker launches and debt refinancing, are positive. However, the Q&A reveals uncertainties in volume growth and payer acceptance. The lack of specific guidance on volume expectations and payer practices raises concerns. Overall, the positive aspects are offset by these uncertainties, leading to a neutral sentiment prediction for the stock price over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
